SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Medical - Healthcare >

Great Basin Scientific Inc. (GBSND)

GBSND RSS Feed
Add GBSND Price Alert      Hide Sticky   Hide Intro
Moderator: Atlanta1, EnergySaver, Stockcaller, TKane, jdporter, kontente
Search This Board: 
Last Post: 4/27/2017 2:38:13 PM - Followers: 459 - Board type: Free - Posts Today: 8

 
 
                             

GBSND http://www.gbscience.com/ 


GREAT BASIN SCIENTIFIC, INC.2441 SOUTH 3850 WEST, SALT LAKE CITY, UT 84210
PHONE: 801-990-1055; TOLLFREE: 888-360-4022; CUSTOMER SUPPORT: 888-333-9793

***4/12/2017 NEWS UPDATE*** 


Announced today (4/12/2017) that it has received CE Marking for its Stool Bacterial PathogensPanelhttp://www.otcmarkets.com/stock/GBSND/news?id=155739


 
***4/3/2017 NEWS UPDATE*** 


FDA 510(k) Premarket Notification - Effective 3/31/2017 - Great Basin Scientific, Inc. - Bordetella Pertussis DNA Assay System:  https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K170284


FYI (Why this particular diagnostic product is so important and useful for healthcare professionals): Pertussis, a respiratory illness commonly known as whooping cough, is a very contagious disease caused by a type of bacteria called Bordetella pertussis. These bacteria attach to the cilia (tiny, hair-like extensions) that line part of the upper respiratory system. The bacteria release toxins (poisons), which damage the cilia and cause airways to swell. Pertussis is a very contagious disease only found in humans. It is spread from person to person. People with pertussis usually spread the disease to another person by coughing or sneezing or when spending a lot of time near one another where you share breathing space. Many babies who get pertussis are infected by older siblings, parents, or caregivers who might not even know they have the disease.

GBSN's most recent 510(k) clearances and applications: 


Great Basin Scientific, Inc. (GBSN) granted 510(k) clearance 3/31/17 by the FDA for Great Basin Bordetella Direct Test
            https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K170284


Great Basin Scientific, Inc. submits 510(k) application to FDA 12/19/16 for diagnostic Stool Bacterial Pathogens Panel.

https://gbscience.com/great-basin-scientific-submits-510k-application-fda-stool-bacterial-pathogens-panel/



Great Basin Scientific Reports Fourth Quarter and Full Year 2016 Results
 
(GlobeNewswire,  March 22, 2017, 07:03:00 AM EDT)

*Company reduces operating costs, improves gross margin and cash burn rate quarter-over-quarter *
 
 
Fourth quarter revenue increased 39% year-over-year; 2016 revenues increased 42%
14% reduction in net cash used in operating activities from the third quarter to the fourth quarter of 2016
34% reduction in fourth quarter G&A expenses leads to 4% reduction in total operating expenses compared to third quarter
Quarterly gross margin improved 42 basis points over third quarter to best level of the year
Percentage of customers using more than one assay increased 17% quarter-over-quarter and 81% year-over-year


SALT LAKE CITY, March 22, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:

GBSN), a molecular diagnostic company, today reported operating results for the fourth quarter and full year ended December 31, 2016.

"The fourth quarter of 2016 was a period of significant progress and change for Great Basin," said Ryan Ashton, co-founder and chief executive officer of Great Basin. "During the third quarter, research and development spending and gross margin inefficiency peaked as we invested in significant menu expansion, which included concurrently running two clinical trials and preparing for the commercial launch of two products that the U.S. Food and Drug Administration (FDA) cleared in early 2016. With those efforts either behind us or winding down, we turned our focus to improving operational efficiencies and implementing cost management programs in preparation for 2017. These efforts resulted in a reduction in sequential quarterly operating expenses and our strongest gross margins of the fiscal year. Furthermore, we expect that the changes we made in the fourth quarter—along with the January completion of the clinical trial for our Bordetella Direct Test and the restructuring and reduction plan we announced in early February—will result in further improvements to our operating expenses, burn rate and gross margins in the first half of 2017."

"Beyond the sequential improvements in gross margins and reduced operating expenses, 2016, overall, was a year of noteworthy progress for the Company. For the first time, we launched two new products and successfully completed two clinical trials in a single year. The doubling of our menu to four assays will promote our objective of continually expanding our customer footprint and increasing our revenue per customer."

Read more: http://www.nasdaq.com/press-release/great-basin-scientific-reports-fourth-quarter-and-full-year-2016-results-20170322-00266#ixzz4dDMOoLMH

 

 



PATENTS



US8936921: METHODS OF ISOTHERMAL APPLICATION USING BLOCKED PRIMERS 
US8637250 : SYSTEMS & METHODS OF POINT-OF-CARE AMPLIFICATION & DETECTION OF POLYNUCLEOTIDES
US20130331298: ANALYZER & DISPOSAL CARTRIDGE FOR MOLECULAR INVITRO DIAGNOSTICS


SEC FILINGS : http://www.nasdaq.com/symbol/gbsn/sec-filings

FACEBOOK PAGE : https://www.facebook.com/gbscience
CEO: RYAN ASHTON

About Great Basin Scientific, Inc: Great Basin Scientific, Inc. (ticker symbol: GBSN) is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. Great Basin's molecular diagnostics system is uniquely capable of answering both the ‘What is it?’ question --answered by a low-cost, low-plex assay-- and the ‘What is causing it?’ question, identified by a multi-plex panel. Great Basin has FDA Clearance on tests for Clostridium difficile and Group B streptococcus. Low-plex tests in development include SA Nasal and Staph ID/R and multi-plex panels being developed include Fungal Pathogens, Shiga-toxin-producing E. coli (STEC) and Food-borne Pathogens (GI Panel). Great Basin Scientific’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. Fast, accurate results. More answers. One easy-to-use and cost-effective system. Only Great Basin delivers a powerful product pipeline of tests and panels that allows every lab to adopt molecular diagnostics that will assist clinicians in better diagnosing and managing patients outcomes. The company sells its diagnostic tests through a direct sales force in the United States, as well as through distributors in the European Union and New Zealand. Great Basin Scientific, Inc. is headquartered in Salt Lake City, UT. For more information on the company or its products, please feel free to contact us at our Corporate Headquarters.

 

 
 
Amended Statement of Ownership (sc 13g/a)
Date: January 24, 2017 @ 4:29 PM
Source: EDGAR (US Regulatory)
Stock: Great Basin Scientific, Inc. (QB) (GBSND)

http://ih.advfn.com/p.php?pid=nmona&article=73684421&symbol=GBSND
NASDAQ : $GBSND


 All iHub stock board posts are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting any content that is off-topic to the stock, which is the subject of the board;
*Posting focused on Admins, Moderators, Users, or post deletions are also off-topic;
*Posting comments, etc. that could be construed as a Personal Attack on another;
*Posting anything that is a Violation of Privacy (no stated consent) is also off-topic;

* Posting statements that are of no value to the stock discussion for board users; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GBSND
Current Price
Volume:
Bid Ask Day's Range
SureTrader
GBSN News: Current Report Filing (8-k) 04/10/2017 09:02:48 AM
GBSN News: USMJ Experiencing High Volume On Verge Of PPS Breakout With Stock Rated Very Bullish And Major Short Position Getting Squeezed 04/06/2017 11:49:40 AM
GBSN News: Annual Report (10-k) 03/22/2017 07:18:09 AM
GBSN News: Current Report Filing (8-k) 03/22/2017 07:01:46 AM
GBSN News: Current Report Filing (8-k) 03/10/2017 07:17:42 AM
PostSubject
#35684  Sticky Note News: http://www.otcmarkets.com/stock/GBSND/news?id=155739 Should trigger a lit sdtrader77 04/12/17 07:13:08 AM
#31968  Sticky Note Great Basin Scientific Receives FDA 510(k) Clearance for kontente 04/04/17 09:20:53 AM
#31897  Sticky Note * * $GBSN Video Chart 04-03-17 * * ClayTrader 04/03/17 05:05:57 PM
#36529   More dilution? Mustangs2008 04/27/17 02:38:13 PM
#36528   GEEZE!-What's-goin'-on??? $1.21's being dumped faster'n old hardboiled eggs Euripides90 04/27/17 02:25:58 PM
#36527   1$ soon peeps yesterdaysnews74 04/27/17 01:58:54 PM
#36526   Cool! Pump it then! GL! Id StockUser 04/27/17 01:56:58 PM
#36525   The company is LOADED with CASH now.... Drugdoctor 04/27/17 01:27:39 PM
#36524   End of the month! Bills & vacation payment Id StockUser 04/27/17 11:45:34 AM
#36523   Who is da #1 CEO? Ryan Ashton!! Id StockUser 04/27/17 10:29:48 AM
#36522   Forget it... only 1800 shares outstanding... WOW! Drugdoctor 04/27/17 08:30:49 AM
#36521   Yes, quarterly RS. .. soon monthly dandan2x72 04/26/17 09:05:45 PM
#36520   When is the next reverse split? They do Kamstock 04/26/17 05:37:49 PM
#36519   One share trades, single share ownership. Wipe out. Nurseusername 04/26/17 03:01:26 PM
#36518   6's, we get upper 50's I'm in, again:) Doubledown75 04/26/17 02:05:53 PM
#36517   Thanks I forgot :) Good luck today Doubledown75 04/26/17 02:03:57 PM
#36516   divide by 2000 Atlanta1 04/26/17 01:25:26 PM
#36515   Atl where we at here pre split? Doubledown75 04/26/17 01:09:59 PM
#36514   LETS-GET-THIS-BACK-UNDER-A-DOLLAR-AGAIN-SO-WE-CAN-DO-ANOTHER-R/S-OH-YEEEAA chris12 04/26/17 11:27:38 AM
#36513   yep. I don't blame people for being gunshy Atlanta1 04/26/17 11:22:58 AM
#36512   Atlanta, Stockscience 04/26/17 11:14:37 AM
#36511   let's hope we all make money here. Atlanta1 04/26/17 11:04:11 AM
#36510   those afraid to buy in the $1.30's will Atlanta1 04/26/17 11:03:12 AM
#36509   Are these the same sharks that had the BRoberts1982 04/26/17 11:02:25 AM
#36508   and what happens when the sharks have agreed Atlanta1 04/26/17 10:55:46 AM
#36507   I think it is obvious, EVEN too the BRoberts1982 04/26/17 10:52:52 AM
#36505   $GBSND - Outstanding shares 1.8 million ... LMAO Drugdoctor 04/26/17 08:18:11 AM
#36504   I think the answer is obvious. Atlanta1 04/26/17 07:31:55 AM
#36503   Really? Was there another shareholder vote that I'm Stockscience 04/26/17 07:01:53 AM
#36502   Another reverse? When? Guess we see less than yesterdaysnews74 04/25/17 10:40:52 PM
#36501   They will R/S then convert the shares. fatcat11 04/25/17 03:55:14 PM
#36500   https://baseballnewssource.com/markets/great-basin-scientific-gbsn-given-media-i thesellerbuyer 04/25/17 11:34:35 AM
#36499   Nope, it's obvious that $3 to $4 targets Drugdoctor 04/25/17 10:13:25 AM
#36498   looks like the MM's have totally stepped back Atlanta1 04/25/17 10:08:45 AM
#36495   yes, I am well aware of GBSN's history. Atlanta1 04/25/17 09:36:15 AM
#36494   I started to become bullish when selling waned Stockscience 04/25/17 09:35:56 AM
#36493   It should be obvious, even to the casual observer, BRoberts1982 04/25/17 09:34:13 AM
#36492   I agree - not even 2 million shares Drugdoctor 04/25/17 09:31:11 AM
#36491   It should be obvious, even to the casual Atlanta1 04/25/17 09:24:42 AM
#36490   Low low volume today = dilution done... bring Drugdoctor 04/24/17 10:34:58 PM
#36489   People still buy this junk? Hilarious! dandan2x72 04/24/17 07:04:10 PM
#36488   Ouch! goodword88 04/24/17 03:39:00 PM
#36487   Same here. Holding 377 shares since pre r/s. Suave85 04/24/17 03:36:14 PM
#36484   I have no idea. I'm stuck here. To Chico Byrd 04/24/17 02:17:58 PM
#36483   How long now till we see the mass selling? yesterdaysnews74 04/24/17 02:15:38 PM
#36482   Low-bids-have-to-fill,B4 can start-to-move-up:Buying just not there no matter Euripides90 04/24/17 12:22:57 PM
#36481   Waiting on the "D" to fall off before Chico Byrd 04/24/17 12:15:33 PM
#36480   They are still diluting though. Rbrassy 04/24/17 11:10:03 AM
#36479   It should be obvious, even to the casual Atlanta1 04/24/17 09:57:56 AM
#36478   Fantastic volume lol Awl416 04/24/17 09:39:56 AM
#36477   So true.."All the SEC ever does anyway is BigMoneyAtl 04/24/17 09:01:03 AM
#36476   Interesting extrapolation but-not-a-"source:"-what teachers were trying to teach Euripides90 04/24/17 07:58:26 AM
#36475   Bravo!!! Nurseusername 04/24/17 06:49:04 AM
PostSubject